[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryotherapy-effect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryotherapy-effect":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,55,89,115,142,167,199,224,252],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100588282","intracoronary-cryotherapy-effect-on-stabilization-of-vulnerable-plaque-in-patients-with-stable-angina-or-acs---a-traditional-feasibility-study-100588282",false,"NCT06939374","Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study","Clinical Investigation of the Efficacy and Safety of Intracoronary Cryotherapy Using the CryoTherapy System (CTS) for High-risk Plaque in Patients With Stable Angina or Acute Coronary Syndrome.","ICECAP","Inclusion Criteria:\n\n* 1\\) Subject is at least 18 years old. 2) Subject has acute cardiac pain\u002Fangina consistent with stable angina or acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:\n\n  1. Non-ST-segment elevation myocardial infarction (NSTEMI) with rise\u002Ffall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring PCI within 72 hours from diagnosis\n  2. Unstable angina\n  3. ST-segment elevation myocardial infarction (STEMI) 3) Successful PCI (defined as diameter stenosis less than 30% and TIMI 3 flow on final angiography without procedural complication) of the culprit lesion.\n\nNOTE: subjects with unstable angina, for whom the culprit lesion as assessed by investigator does not require PCI currently or within the next 6 months (subject treated with optimal medical treatment) can be enrolled in the study.\n\n4\\) Subject has at least one high-risk plaque meeting the criteria below:\n\n1. Located in a non-culprit vessel,\n2. High-risk plaque lesion on CCTA and at least one of the following features:\n\n   1. Presence of low-attenuation plaque (HU\\\u003C50) and\u002For\n   2. Positive remodelling (remodelling index \\>1.1) and\u002For\n   3. Napkin ring sign and\u002For\n   4. Plaque burden ≥70%\n3. Lesion length ≤ 20 mm.\n4. Diameter stenosis on invasive angiography between 30% and 70% on coronary angiogram or negative physiology assessment (FFR\\>0.80 or NHPR\\>0.89).\n5. Reference vessel diameter (RVD) \\\u003C 3.75 mm and \\> 2.50 mm in diameter\n6. Investigator considers that lesions are accessible.\n7. If more than two suitable lesions available, investigator will select the most appropriate lesion for cryotherapy treatment.\n\n   5\\) maxLCBI4mm in the lesion \\> 324.7 6) Subject is able to provide consent and has signed and dated the informed consent form.\n\n   Exclusion Criteria:\n   * 1\\) Subject is hemodynamically unstable (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).\n\n     2\\) Subject has ongoing ST-segment elevation myocardial infarction. 3) Subject had a procedural complication during the ACS PCI procedure. 4) Subject has history of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.\n\n     5\\) Subject has known reduced Left Ventricular Ejection Fraction \\\u003C 30%. 6) Subject has known severe valvular heart disease. 7) Subject has known severe renal insufficiency (eGFR \\\u003C30 ml\u002Fmin\u002F1.72 m2). 8) Subject has any life-threatening conditions or medical comorbidity resulting in life expectancy \\\u003C 12 months.\n\n     9\\) Subject is currently participating in another clinical investigation that has not yet reached its primary endpoint.\n\n     10\\) Subject has severe peripheral vascular disease impeding femoral artery access.\n\n     11\\) Subject is pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or is a female with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).\n\n   Angiographic exclusion criteria:\n   1. Visible distal embolization\u002Fno-reflow following culprit lesions PCI.\n   2. Left main coronary artery disease (visual diameter stenosis \\> 50%).\n   3. Stent thrombosis\u002Frestenosis as a culprit lesion.\n   4. CTS lesion involving a bifurcation (defined as lesions involving side branches \\>2.0 mm).\n   5. Angiographic or CCTA evidence of severe calcification and\u002For marked tortuosity of the index vessel and\u002For lesion.\n   6. Thrombotic lesions.\n   7. Ostial lesions.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","ICECAP is a multi-centre, prospective, single-arm, interventional, traditional feasibility clinical investigation to evaluate the efficacy and safety of intra-coronary cryotherapy on vulnerable or high-risk plaque (HRP), using the CryoTherapy System (CTS). The study aims to enroll 25 patients with symptomatic coronary artery disease, successfully treated for their culprit lesion and with presence of at least one HRP lesion in another vessel. Eligible patients will undergo cryotherapy during a planned procedure. Near-infrared spectrometry (NIRS and Optical Coherence Tomography imaging will be used during baseline procedure, and during a 9 months follow visit. The primary endpoint is reduction of plaque burden measured as 30% reduction in maxLCBI4mm as measured by NIRS at 9 months post procedure.",[27,28,29,30,31,32,33],"Coronary Arterial Disease (CAD)","Plaque","Vulnerable Plaque","Cryotherapy","Cryotherapy Effect","Coronary Balloon","Atherosclerosis Coronary Artery With Angina Pectoris",[35,36,37,38,39,40,41],"Medical device","traditional feasibility","Single Group","Device Feasibility","Multi-Center","Prospective","Interventional","RECRUITING","2026-03-31",{"date":45,"type":46},"2026-04-06","ACTUAL",{"date":48,"type":46},"2025-03-01",{"date":50,"type":21},"2027-06-30",{"name":52,"class":53},"Cryotherapeutics SA","INDUSTRY",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100613303","this-clinical-trial-aims-to-compare-the-effectiveness-of-two-intra-pulpal-cryotherapy-techniques-endo-ice-and-ice-sticks-in-decreasing-intra-operative-pain-and-enhancing-the-success-of-local-anesthesia-during-pulpectomy-of-mandibular-molars-with-symptomatic-irreversible-pulpitis-100613303","NCT07264829","This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks-in Decreasing Intra-operative Pain and Enhancing the Success of Local Anesthesia During Pulpectomy of Mandibular Molars With Symptomatic Irreversible Pulpitis.","Comparative Analysis of Intra-pulpal Cryotherapy Methods During Pulpectomy in Molars With Symptomatic Irreversible Pulpitis: A Randomized Control Trial","Inclusion Criteria:\n\n1. Individuals (Male and Female) aged 18 to 40 years.\n2. Healthy individuals with no significant present and past medical findings.\n3. Mandibular molars.\n4. Symptomatic irreversible pulpitis (moderate to severe pain according to VAS 4-10).\n5. Periapical index (PAI) Score: 1-3 on periapical radiograph.\n6. DAS-R: 4-14( mild to moderate anxiety)\n\nExclusion Criteria:\n\n1. Immature teeth with open apices.\n2. Calcified pulp chamber and canals.\n3. Periodontally compromised teeth.\n4. Individuals who had taken steroids, analgesics, or antibiotics within the last 48 hours.","40 Years",{"count":64,"type":21},90,[24],"The goal of this clinical trail is to compare the analgesic effect of endo-ice and ice-sticks in reducing intra-operative pain during pulpectomy in molars with Symptomatic Irreversible Pulpitis. Principal Investigator will perform the procedure and outcome assessor will interview the participants as well as fill the pre-operative questionnaire. The patient will be instructed beforehand on how to score their pre-operative, intra-operative and post-operative intensity of pain according to Visual Analogue Scale.The Anxiety level of patient will also be recorded according to the Corah's Dental Anxiety Scale questionnaire and their level of anxiety before and after the intervention will be recorded by the outcome assessor.\n\nThe principal investigator will perform all endodontic procedures, with the outcome assessor blinded to the cryotherapy method. Prior to administering IANB, a topical anesthetic gel will be applied. A 27-gauge needle will deliver 1.8 ml of 2% lidocaine with 1:100,000 epinephrine at a rate of 1 ml\u002Fmin. After a 5-minute wait, anesthesia effectiveness will be confirmed through electric pulp testing (EPT) on a neighboring tooth, with two consecutive negative responses confirming success. Once adequate anesthesia is confirmed, an access opening will be made under rubber dam isolation for the procedure.\n\n1. CONTROL GROUP: After access opening and complete de-roofing of the pulp chamber, pulpectomy of the inflamed pulp will be performed under the given effective IANB with no additional intervention to control intra-operative pain.\n2. ENDO-ICE GROUP: After access opening, pulp will be exposed and de-roofing will be performed. Endo-ice with the help of cotton pellet will be applied inside the pulp chamber for 2min (8 consecutive applications, 15sec each) and pulpectomy of the inflammed pulp will be performed immediately.\n3. ICE-STICKS GROUP: Following the access opening and complete de-roofing of pulp chamber, four ice sticks will be placed inside the pulp chamber for 2 minutes (30 seconds each, using tweezer). Subsequently, pulpectomy of the inflamed pulp will be performed immediately.\n\nPatients will be asked to rate their level of pain to the outcome assessor at four specific intervals during the trial, i.e., pre-operative (before local anesthesia), pre-operative (after local anesthesia), during pulpectomy and immediately after pulp extirpation and it will be recorded in a proforma by the blinded outcome assessor.\n\nPain and Anxiety Scores will be compared to asses either cryotherapy or which method of cryotherapy found to be effective in reducing intra-operative pain.",[68,69,70,31],"Root Canal Treatment","Intra-operative Pain","Symptomatic Irreversible Pulpitis",[30,72,73,74,75,76,70],"Endodontic treatment","Intra-operative pain","Pulpectomy","Endo-ice","Ice-sticks","NOT_YET_RECRUITING","2026-03-11",{"date":80,"type":46},"2026-03-13",{"date":82,"type":21},"2026-04-15",{"date":84,"type":21},"2026-10-30",{"name":86,"class":87},"Dow University of Health Sciences","OTHER",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":88},"100388544","phase-3-cryoablation-in-combination-or-not-with-pembrolizumab-and-pemetrexed-carboplatin-in-1st-line-treatment-for-patients-with-metastatic-lung-adenocarcinoma-100388544","NCT04339218","Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study","CRYOMUNE","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed non-small lung adenocarcinoma.\n2. Metastatic disease.\n3. Treatment with pembrolizumab in combination with pemetrexed-carboplatin as per market authorization.\n4. At least two target lesions (RECIST1.1), measurable with CT or MRI :\n\n   1. One target lesion that is amenable for accurate repeated measurements,\n   2. One target lesion (15-40 mm) that is amenable for cryoablation treatment including lung, kidney, adrenal, soft tissue and lytic bone lesions. Liver and sclerotic bone lesions are not allowed to be treated by cryoablation.\n5. Age ≥ 18.\n6. Performance status ≤ 2.\n7. Women of childbearing potential must have a negative serum pregnancy test prior to registration.\n8. Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia)\n9. Patients with a social security in compliance with the French law (Loi Jardé).\n10. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n11. Voluntarily signed and dated written informed consents prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Squamous cell tumors and other than adenocarcinoma.\n2. Prior systemic treatment for advanced non-small cell lung cancer (except adjuvant therapy after complete resection).\n3. Current or prior use of immunosuppressive medication including any use of oral glucocorticoids, within 21 days before the first dose of pembrolizumab.\n4. Known contra-indication and\u002For hypersensitivity to PD1\u002FPD-L1 antagonist and\u002For cytotoxic therapy.\n5. Known contra-indication to cryoablation.\n6. Abnormal coagulation contraindicating biopsy.\n7. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma or incidentally discovered good prognosis prostate cancer (T stage \\\u003C pT3 and Gleason ≤ 7).\n8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.\n9. Subjects who participated in an investigational drug or device study within 28 days prior to study entry.\n10. Known infection with HIV, hepatitis B, or hepatitis C.\n11. Females who are pregnant or breast-feeding.\n12. Men or women refusing contraception.\n13. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.\n14. Previous enrolment in the present study.\n15. Individuals deprived of liberty or placed under legal guardianship.",{"count":98,"type":21},214,[100],"PHASE3","This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients.\n\nThis is a multicenter, prospective, open-labeled, 2-arm comparative randomized (1:1) phase III trial.\n\nPatients will be randomized with a 1:1 ratio into:\n\n* Arm A (experimental arm): cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.\n* Arm B (standard arm): pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.\n\nPembrolizumab and pemetrexed-carboplatin will be prescribed and administered at the dose recommended by market authorization.\n\nCryoablation treatment should be performed within 6 weeks after the first administration of pembrolizumab. No treatment switching permitted.",[103,31],"Lung Adenocarcinoma",[105],"Lung adenocarcinoma, immunotherapy, cryoablation","2026-01-28",{"date":108,"type":46},"2026-01-30",{"date":110,"type":46},"2020-08-28",{"date":112,"type":21},"2028-08-27",{"name":114,"class":87},"Institut Bergonié",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":88},"100446628","utility-of-intermittent-cryo-compression-versus-traditional-icing-following-arthroscopic-rotator-cuff-repair-100446628","NCT05095909","Utility of Intermittent Cryo-Compression Versus Traditional Icing Following Arthroscopic Rotator Cuff Repair","ICC","Inclusion Criteria:\n\n1. Patients who are candidates for arthroscopic rotator cuff repair\n\n   1. Acute, traumatic tear of the rotator cuff in an active patient\n   2. Chronic, symptomatic tear of the rotator cuff in an active patient having failed non - operative treatment\n2. Patient agreeable to participation in the study and able to complete informed consent process and all study requirements.\n3. ≥18 years of age\n\nExclusion Criteria:\n\n1. Pregnancy (per pre-operative physical)\n2. Presence of significant glenohumeral joint osteoarthritis\n3. Age over 70\n4. History of clinically diagnosed lymphedema\n5. Morbid obesity (BMI \\> 45)\n6. History of drug or alcohol addiction, prior opioid dependence, or current use of opioid medication (preoperative)\n7. Investigators concern regarding subject's ability or willingness to follow protocol.\n8. History of significant vascular impairment in the affected region (e.g., from prior frostbite, diabetes, arteriosclerosis or ischemia).\n9. History of acute paroxysmal cold hemoglobinuria or cryoglobulinemia.\n10. History of Raynaud's disease or cold hypersensitivity (cold urticarial).",true,"70 Years",{"count":125,"type":21},100,[24],"Effective post - operative pain control following orthopedic surgical procedures without excessive reliance upon opioid pain medication has garnered increased attention in recent years. This study will evaluate the utilization of a non-invasive, novel cryo - compression, post-operative modality to improve pain control versus standard ice wraps in the immediate post-operative phase of arthroscopic rotator cuff surgery via a randomized controlled study design. Furthermore, if this study demonstrates improved pain control, improved quality of life and decreased opioid usage with the intermittent cold compression unit, recommendations may be considered for system-wide utilization.",[129,31],"Rotator Cuff Injuries",[131,132],"Cryo-compression","Rotator cuff repair","2026-01-26",{"date":135,"type":46},"2026-01-27",{"date":137,"type":46},"2024-08-05",{"date":139,"type":21},"2026-12",{"name":141,"class":87},"Allina Health System",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":122,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":88},"100551144","vibracool-device-to-reduce-pain-and-opioid-use-after-anterior-cruciate-ligament-reconstruction-aclr-100551144","NCT06456268","VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)","Clinical Evaluation of an External Neuromodulation Device (VibraCool) to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)","Inclusion Criteria:\n\n* Underwent ACL reconstruction\n\nExclusion Criteria:\n\n* Pediatric iliotibial band ACL reconstruction (known to cause significantly more pain)\n* Non-english speakers (limitations of our study group)",{"count":150,"type":21},130,[24],"The goal of this project is to test the effects of the VibraCool mechanical stimulation neuromodulatory therapeutic device on post-operative pain and opioid use following anterior crucitate ligament reconstruction (ACLR), and thus residual opioids in circulation.",[154,155,31,156,157],"ACL","Opioid Use","Vibration; Exposure","Pain, Postoperative","2026-01-06",{"date":160,"type":46},"2026-01-07",{"date":162,"type":21},"2026-06",{"date":164,"type":21},"2026-11-30",{"name":166,"class":87},"Columbia University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":174,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":177,"studyType":178,"phases":4,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100543512","national-registry-of-surgical-treatment-and-percutaneous-cryoablation-of-parietal-endometriosis-100543512","NCT06356831","National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis","Endomercyo","Inclusion Criteria:\n\n* Presence of parietal endometriosis: with suggestive clinical and imaging criteria (MRI and ultrasound)\n* Symptomatic parietal endometriosis (VAS \\> 3 OR bothersome bleeding OR reported impact on quality of life)\n\nExclusion Criteria:\n\n* Endometriosis not affecting the anterior wall of the abdomen (as deep pelvic muscle: ilio-psoas, obturators, perineal, ischio-anal fossa)\n* Minor patient (\\\u003C 18 years)\n* Pregnant patient at any trimester\n* Patient with hemostasis disorders (constitutional or acquired)\n* Patient with systemic infection or localized scar infection upon inclusion.\n* Patient with contraindications to MRI\n* Female patient with a planned medical or surgical procedure for the duration of the study that may interfere with the proper conduct of the study.\n* Patient unable to understand the information provided\n* Patient who is not affiliated to the social security system\n* Patient under curatorship or tutorship\n* Patient with a nodule of primary or secondary malignant tumor origin","FEMALE",{"count":176,"type":21},300,"3 Years","OBSERVATIONAL","National multicentric registry of a cohort of patient with suffering parietal endometriosis, carried out by a multidisciplinary radiosurgery team",[181,31,182,183],"Endometriosis","Surgical","Radiology",[185,186,187,188],"endometriosis","Cryo ablation","Surgical operation","radiology","2025-11-26",{"date":191,"type":46},"2025-11-28",{"date":193,"type":46},"2024-06-15",{"date":195,"type":21},"2028-01-31",{"name":197,"class":87},"Centre Hospitalier Intercommunal Creteil",18,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":122,"sex":17,"minAge":206,"maxAge":62,"enrollmentInfo":207,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":88},"100599217","percutaneous-intercostal-cryoneuromodulation-onset-timing-100599217","NCT07081620","Percutaneous Intercostal Cryoneuromodulation Onset Timing.","How Long Does it Take for Percutaneous Intercostal Cryoneuromodulation to Produce Cryoanalgesia? A Prospective Observational Study.","Inclusion Criteria:\n\n* Patients who are undergoing preoperative percutaneous intercostal cryoneurolysis for pectus excavatum surgery\n\nExclusion Criteria:\n\n* failure to obtain consent","12 Years",{"count":208,"type":21},20,"Percutaneous Intercostal Cryoneurolysis is a promising technique that addresses acute postoperative pain after Nuss procedure for pectus excavatum. However its onset timing has not yet been determined. A physical examination would assess the variation of chest skin sensitivity to soft touch, cold (water at 4°C), and heat (water at 40°C) through days following the cryoneurolysis procedure.",[31,211],"Pectus Excavatum",[213,214],"Cryoneurolysis","Cryoneuromodulation","2025-07-22",{"date":217,"type":46},"2025-07-23",{"date":219,"type":46},"2025-06-07",{"date":221,"type":21},"2026-11",{"name":223,"class":87},"Papa Giovanni XXIII Hospital",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":122,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100562874","acute-effects-of-cryotherapy-on-muscle-properties-100562874","NCT06608836","Acute Effects of Cryotherapy on Muscle Properties","Acute Effects of Cryotherapy on Muscle Mechanical Properties and Muscle Activation Changes","Inclusion Criteria:\n\n* Being willing to participate in the study\n* Being between the ages of 18 and 35\n\nExclusion Criteria:\n\n* Having undergone orthopedic surgery involving the lower extremity","35 Years",{"count":233,"type":21},52,[24],"The main aim of this study is to investigate the acute effects of cryotherapy on muscle mechanical properties, muscle strength, and activation changes in healthy subjects.",[31],[238,239,240,241,242],"cryotherapy","muscles","acute effect","muscle strength","electromyography","2024-09-20",{"date":245,"type":46},"2024-09-23",{"date":247,"type":21},"2024-12-15",{"date":249,"type":21},"2025-01-15",{"name":251,"class":87},"Istanbul University - Cerrahpasa",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":122,"sex":17,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":88},"100553875","a-cryotherapy-with-tranexamic-acid-versus-normal-saline-in-the-treatment-of-melasma-100553875","NCT06491771","A Cryotherapy With Tranexamic Acid Versus Normal Saline in the Treatment of Melasma","A Randomized Split-face Study of a Precision Cryotherapy Via Boosting Mode Combined With Tranexamic Acid Versus Normal Saline in the Treatment of Melasma","Inclusion Criteria:\n\n* The patients diagnosed with epidermal-type melasma sized equal to or more than 2 cm on both sides of cheeks\n* Fitzpatrick skin type II-IV\n\nExclusion Criteria:\n\n* Pregnant or lactation\n* Subjects who have been treated with any kind of energy-based device 6 months prior to the inclusion\n* Subjects who have been treated with topical or oral treatment for melasma 6 months prior to the inclusion\n* Subjects who allergy to cryotherapy such as cryoglobulinemia, cold urticaria, and abnormal cold tolerance\n* Subjects with abnormal sensation such as diabetes mellitus\n* Active skin infections\n* History of hypertrophic scars or keloids History of hypertrophic scars or keloids","25 Years","60 Years",{"count":198,"type":21},[24],"This study aimed to evaluate the effectiveness of a precision cryotherapy via boosting mode combined with tranexamic acid versus normal saline in the treatment of melasma. Eighteen patients aged 25 to 60 years diagnosed with epidermal-typed melasma sized equal to or more than 2 cm on both cheeks were included. The patients were treated with a precision cryotherapy via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week. Then, they were follow up at 1 and 3 months after the last treatment. Subjective assessment of physician and patient improvement were evaluated. Moreover, Melasma Area and Severity Index (MASI), melanin and erythema index using Mexameter were also recorded.",[31],"2024-07-03",{"date":267,"type":46},"2024-07-09",{"date":269,"type":21},"2024-07-01",{"date":271,"type":21},"2025-07-01",{"name":273,"class":87},"Mahidol University"]